Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEAP-SE: EEG for Antidepressant Prediction
NCT04388202Phase 4Withdrawn
- Sponsor
- Alto Neuroscience
- Start
- Oct 2020
- Primary completion
- May 2023
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, single-blind trial in major depressive disorder (MDD) comparing Sertraline with Escitalopram (2 arms). Primary endpoint: Response rate on the Quick Inventory of Depressive Symptoms at 8 weeks. Planned start Oct 2020; status: withdrawn.
02
Drugs
sertralineescitalopram
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04388202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04388202.